Home › Research › Biomarkers
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals
Petrice M Cogswell, Heather J Wiste, Terry M Therneau, Michael E Griswold, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Alexa Pichet Binette, Erik Stomrud et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-09
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
The study included 381 MCSA and 584 BioFINDER-2 participants. Amyloid PET and percent phosphorylated to non-phosphorylated tau217 (%p-tau217) were strong predictors of progression to MCI in both cohorts: hazard ratios of 1.49 and 1.23 in the MCSA and 1.72 and 1.65 in BioFINDER, respectively. Amyloid beta 42/40 was a significant predictor in BioFINDER-2 only (hazard ratio 2.20). Plasma %p-tau217 was associated with progression from CU to MCI in both cohorts, although differences in biomarker associations may be related to differences in the two cohorts. HIGHLIGHTS: Mass-spectrometry-based plasma phosphorylated tau217 was associated with cognitively unimpaired to mild cognitive impairment (MCI) progression. Plasma amyloid beta 42/40 was a significant predictor in BioFINDER but not the Mayo Clinic Study of Aging (MCSA). Amyloid positron emission tomography (PET) was the strongest predictor of progression to MCI in the MCSA. Plasma had added value to amyloid PET in BioFINDER but not the MCSA. Biomarker performance may vary with cohort and biomarker measurement differences.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cogswell, P. M., Wiste, H. J., Therneau, T. M., Griswold, M. E., Mattsson-Carlgren, N., Palmqvist, S., et al. (2025). Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70625
Vancouver
Cogswell PM, Wiste HJ, Therneau TM, Griswold ME, Mattsson-Carlgren N, Palmqvist S, et al. Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70625. PMID: 40883967.
BibTeX
@article{cogswell2025-40883967,
author = {Cogswell, Petrice M and Wiste, Heather J and Therneau, Terry M and Griswold, Michael E and Mattsson-Carlgren, Niklas and Palmqvist, Sebastian and Binette, Alexa Pichet and Stomrud, Erik and others},
title = {{Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70625},
pmid = {40883967},
url = {https://doi.org/10.1002/alz.70625}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The study included 381 MCSA and 584 BioFINDER-2 participants.
- Amyloid PET and percent phosphorylated to non-phosphorylated tau217 (%p-tau217) were strong predictors of progression to MCI in both cohorts: hazard ratios of 1.49 and 1.23 in the MCSA and 1.72 and 1.65 in BioFINDER, respectively.
- Amyloid beta 42/40 was a significant predictor in BioFINDER-2 only (hazard ratio 2.20).
- Plasma %p-tau217 was associated with progression from CU to MCI in both cohorts, although differences in biomarker associations may be related to differences in the two cohorts.
- HIGHLIGHTS: Mass-spectrometry-based plasma phosphorylated tau217 was associated with cognitively unimpaired to mild cognitive impairment (MCI) progression.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants381
- Evidence strengthModerate
How this study scored 59/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 33 of the 56 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 381 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40883967) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 33 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 33 of the 56 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.